Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Clarify the therapeutic differences between robot assisted endoscopic clearance and traditional puncture and external drainage, and establish a new minimally invasive surgical diagnosis and treatment strategy for intraventricular hemorrhage
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Robot assisted endoscopy group | Experimental | Using robot assisted endoscopy to clear intraventricular hemorrhage |
|
| External ventricular drainage group | Active Comparator | Using External ventricular drainage to clear intraventricular hemorrhage |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Using robot assisted endoscopy to clear intraventricular hemorrhage | Procedure | More advanced surgical auxiliary instruments are used to improve surgical accuracy |
|
| Measure | Description | Time Frame |
|---|---|---|
| 6-month mRS score | MRS Scores 6 months after onset | 180 days |
| Measure | Description | Time Frame |
|---|---|---|
| 30 day mortality rate | Mortality at 30 days after onset | 0-30 days |
Not provided
Inclusion Criteria:
Age range from 18 to 80 years old;
The time from onset to first CT confirmation of intraventricular hemorrhage is less than 24 hours;
Before enrollment, CT confirmed that the intraventricular hemorrhage score (modified Graeb score) was ≥ 8 points, and the total score of bilateral lateral ventricles was ≥ 5 points;
If there is concurrent cerebral hemorrhage but the hematoma volume is less than 30ml;
⑤ First CT to surgery time<72 hours;
⑥ GCS ≤ 14.
Exclusion Criteria:
â‘ Suspected (unless excluded by angiography or CTA/MRA/MRI) or untreated rupture of cerebral aneurysm, Moyamoya disease, intracranial AVM rupture, or tumor;
Patients with a GCS score of 3 and/or fixed dilated pupils and/or no spontaneous breathing;
Patients with pre-existing neurological disorders that affect neurological function assessment prior to onset;
Coagulation dysfunction;
Patients who require long-term anticoagulant treatment;
⑥ Use dabigatran, apixaban, and/or rivaroxaban (or drugs of the same class) before symptoms appear; ⑦ Platelet count<100 × 109/L, INR>1.4;
â‘§ Pregnancy (positive serum or urine pregnancy test);
⑨ Subtentorial hemorrhage or brainstem hemorrhage;
â‘© Patients who have previously participated in other interventional clinical studies and participated in observational, natural history, and/or epidemiological studies that do not involve intervention are eligible;
⑪ Subjects who are expected to not survive until the 180th day of visit; No written informed consent was given by the subjects or legal representatives.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|